1. Introduction {#sec1-cancers-12-00344}
===============

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, as they have been proven to be more efficacious and less toxic than conventional chemotherapy or targeted therapies in several tumor types. However, some patients experience an unexpected accelerated tumor growth during treatment associated with prompt clinical deterioration. This phenomenon has been defined as hyperprogressive disease (HPD) \[[@B1-cancers-12-00344],[@B2-cancers-12-00344],[@B3-cancers-12-00344]\]. The underlying mechanisms are still not clearly defined, although some recent studies are shedding light upon the matter. Tumor infiltration by M2-like CD163^+^ CD33**^+^** PD-L1**^+^** macrophages was found in tumor biopsies from all non small cell lung cancer (NSCLC) patients exhibiting hyperprogression. Tumor progression was shown to correlate with anti-PD1 Fc interaction with Fc receptors in macrophages in a murine xenograft model \[[@B4-cancers-12-00344]\]. A recent translational study in gastric cancer found an increase of proliferating Ki67**^+^** regulatory T cells (Tregs) in tumor samples of HPD patients, and confirmed stronger immune suppressive activities of these cells in vitro after anti-PD1 exposure \[[@B5-cancers-12-00344]\].

Several definitions for HPD based on radiological criteria, sometimes complemented with clinical outcomes, have been proposed so far \[[@B1-cancers-12-00344],[@B2-cancers-12-00344],[@B6-cancers-12-00344],[@B7-cancers-12-00344]\]. Most of them quantify the change in tumor growth rates before and after immunotherapy, and consider HPD when a predetermined cut off value of increment in tumor growth rate is surpassed. However, due to the very nature of radiological evaluations, all criteria face important limitations that preclude their applicability in different situations. A progression caused by non-measurable disease or the unavailability of previous radiological tests are amongst different drawbacks. Additional biological information that could be obtained using noninvasive techniques includes the evaluation of the immunological *status quo*. This information might complement the definition of HPD and help to improve and even anticipate its detection.

We have recently demonstrated that functional systemic CD4 T cell immunity is required for a clinical response to immune checkpoint inhibitors in NSCLC patients who had progressed to platinum-based chemotherapy \[[@B8-cancers-12-00344]\]. Hence, we classified patients in two groups according to systemic CD4 T cell functionality. G1 patients showed proficient CD4 T cell immunity before the start of immunotherapy, characterized by good proliferative responses and low coexpression of PD-1 and LAG-3 after activation. On the other hand, G2 patients showed highly dysfunctional CD4 responses, with strong coexpression of PD-1 and LAG-3. While G2 patients did not respond to immunotherapy, G1 patients included objective responders who showed an expansion of the CD28+ T cell populations after the first cycle of therapy \[[@B8-cancers-12-00344]\], in agreement with other studies \[[@B9-cancers-12-00344],[@B10-cancers-12-00344]\]. The expression of CD28 in T cells is frequently used as a maker of differentiation. Thus, poorly- and intermediately-differentiated T cells express CD28, while highly differentiated cells do not \[[@B11-cancers-12-00344],[@B12-cancers-12-00344]\]. Indeed, G1 and G2 patients can be readily identified by quantifying the relative percentage of CD4 T~HD~ cells within CD4 cells in peripheral blood before starting immunotherapies. While G1 patients are characterized by having more than 40% of CD4 T~HD~, G2 patients show less than 40% CD4 T~HD~ \[[@B8-cancers-12-00344]\]. This classification constituted a first criterion for the identification of non-responder versus potential responder patients. We also found that all patients presented systemic CD4 T cells with mainly Th17 phenotypes, without differences between responders and progressors, and without significant differences in the percentage of lung-cancer-specific CD4 or CD8 T cells \[[@B8-cancers-12-00344]\]. However, CD4 T cells from progressors were highly dysfunctional in proliferation but not in cytokine production.

While an expansion of CD28+ populations marks responders \[[@B8-cancers-12-00344],[@B9-cancers-12-00344],[@B10-cancers-12-00344]\], it is likely that an expansion of CD28- populations (highly-differentiated T cells) is a marker for failure regarding immunotherapy. The present study furthers analyzes the immune profiles of our cohort for diagnostic markers of HPD.

2. Results {#sec2-cancers-12-00344}
==========

2.1. Patients and Clinical Outcomes {#sec2dot1-cancers-12-00344}
-----------------------------------

In the present study, a cohort of 70 lung cancer patients were included, i.e., 51 (72.9%) with nonsquamous NSCLC and 19 (27.1%) with squamous NSCLC. Atezolizumab was the most frequently prescribed treatment (33 patients; 47.1%), followed by nivolumab (28 patients; 40%), and pembrolizumab (9 patients; 12.9%). The majority (50 patients; 71.4%) had received one previous line of treatment for metastatic disease. Fifteen patients (21.4%) were of poor prognosis according to the Gustave Roussy Immune Score (GRIm-Score) \[[@B13-cancers-12-00344]\], while 37 (52.9%) had good prognostic characteristics. According to the Lung Immune Prognostic Index (LIPI), 5 patients (7.1%) were of poor prognosis while 57 (81.5%) were classified as good or intermediate prognosis. According to G1/G2 classification on systemic CD4 T cell functionality as defined by Zuazo M et al. \[[@B8-cancers-12-00344]\], 38 patients (52.9%) presented a G1 profile (\>40% baseline CD4 T~HD~) and 31 (44.3%) had a G2 profile (\<40% baseline CD4 T~HD~) ([Table 1](#cancers-12-00344-t001){ref-type="table"}).

Overall response rate (ORR) was 24%, and 9% of the patients presented stable disease (SD). Median progression-free survival (mPFS) was 8.9 weeks, and median overall survival (mOS) was 48.1 weeks.

The incidence of HPD in our cohort study was 17.9% (95% CI 9.6 to 29.4). In HPD patients, the mPFS was significantly lower (6 weeks; 95% CI 4.9 to 7.1) compared with all other patients (10.9 weeks; 95% CI 6.3 to 15.4) (*p* \< 0.001) ([Figure 1](#cancers-12-00344-f001){ref-type="fig"}A), even when considering only progressors (*p* = 0.044) ([Figure 1](#cancers-12-00344-f001){ref-type="fig"}B). mOS in HPD patients was 14.0 weeks (95% CI, 6.5 to 21.5) and 54.7 weeks (95% CI, 36.7 to 72.8) for all other patients (*p* = 0.006) ([Figure 1](#cancers-12-00344-f001){ref-type="fig"}C).

The association of HPD with G1/G2 CD4 T cell profiles was analyzed in the whole cohort of patients ([Figure 2](#cancers-12-00344-f002){ref-type="fig"}A), as well as with other variables ([Supplementary Figure S1](#app1-cancers-12-00344){ref-type="app"}). While objective responders were found in G1 patients (\>40% baseline CD4 T~HD~), HPD was detected within G2 patients. No significant association was observed with baseline CD8 T~HD~ profiles ([Figure 2](#cancers-12-00344-f002){ref-type="fig"}B). Indeed, HPD was very significantly associated with a baseline G2-type of systemic CD4 T cell profile as defined by Zuazo et al. (*p* = 0.003 by Pearson's Chi Square test) within progressors, which identifies patients with dysfunctional CD4 immunity before the start of immunotherapy \[[@B8-cancers-12-00344]\]. The HPD proportion was of 3.3% for patients with G1 profile and 37.5% for patients with G2 profile ([Figure 1](#cancers-12-00344-f001){ref-type="fig"}C). A significant correlation was found between HPD and smoking (*p* = 0.035). No interaction was found between HPD and the immunotherapy drug (*p* = 0.440), GRIm (*p* = 1) or any of its variables, i.e., LIPI of poor prognosis (p = 1.000), number of previous treatments (p = 0.151), gender (*p* = 1.000), age (*p* = 0.072), performance status (*p* = 0.189), tumor histology (*p* = 1.000), PD-L1 tumor expression (*p* = 0.599), number of affected organs (*p* = 0.707) or liver metastases (*p* = 0.707).

2.2. Systemic Expansion of CD28-Negative CD4 T Cells (T~HD~ Cells) within the First Cycle of Therapy Is Significantly Associated with HPD {#sec2dot2-cancers-12-00344}
-----------------------------------------------------------------------------------------------------------------------------------------

Although a significant correlation of HPD with a baseline G2 profile was observed ([Figure 2](#cancers-12-00344-f002){ref-type="fig"}), it was not sufficient to separate G2 progressors from hyperprogressors. Along with others, we have shown that a systemic expansion of CD28+ CD4 T cells following the start of immunotherapy is characteristic in responder patients. Therefore, we decided to determine whether changes in the highly differentiated CD28-negative (T~HD~) CD4 populations from baseline to first cycle of therapy would be an indicator to further discriminate HPD from non-HPD progressors.

We observed that 13 (46.4%) of the patients with a G2 profile presented a sharp expansion of the highly differentiated CD4 T cell compartment which correlated with very poor outcome ([Figure 3](#cancers-12-00344-f003){ref-type="fig"}A,B). After normalizing the data, we then compared the relative change of the percentage in CD4 T~HD~, as defined in materials and methods. When stratified by non-HPD and HPD using radiological criteria, ΔCD4 T~HD~ was significantly higher for the latter (median 1.525 vs. 0.990; *p* = 0.0007) ([Figure 3](#cancers-12-00344-f003){ref-type="fig"}C). Interestingly, HPD patients also presented a higher ΔCD4 T~HD~ when comparing with responders and with non-HPD progressors (median 1.525, 0.970 and 1.000 respectively; *p* = 0.0025), while no differences were found between these two last groups of patients (*p* \> 0.05 by Bonferroni's Multiple Comparison Test) ([Figure 3](#cancers-12-00344-f003){ref-type="fig"}D). ROC analysis provided a cut-off value of ΔCD4 T~HD~ ≥ 1.3 to identify HPD with 82% specificity and 70% sensitivity, with an area under the curve (AUC) of 0.792 ([Figure 3](#cancers-12-00344-f003){ref-type="fig"}E). Accordingly, an increase of ΔCD4 T~HD~ ≥ 1.3 (from now "CD4 T~HD~ burst") was very significantly associated with HPD (*p* = 0.008 by Fisher's exact test) ([Figure 3](#cancers-12-00344-f003){ref-type="fig"}F).

2.3. Association between CD4 T~HD~ Cell Expansion and Clinical Outcomes {#sec2dot3-cancers-12-00344}
-----------------------------------------------------------------------

To confirm the role of CD4 T cell dynamics in the response to immunotherapy in NSCLC, we evaluated the correlation of CD4 T~HD~ burst with clinical outcomes. Patients presenting a CD4 T~HD~ burst following the first cycle of PD-L1/PD-1 blockade had significantly shorter mPFS compared to the rest of patients (6.29 vs. 9.86 weeks, *p* = 0.001). These patients had all progressed within 11 weeks after the first cycle of treatment ([Figure 3](#cancers-12-00344-f003){ref-type="fig"}E). No significant differences in PFS were found when considering only progressors (*p* = 0.250), although the curves were similar to those obtained by radiological identification of HPD by TGR ([Figure 4](#cancers-12-00344-f004){ref-type="fig"}A). Likewise, a trend towards decreased mOS was observed in the cohort of patients exhibiting a CD4 T~HD~ burst (56.1 weeks; 95% CI 30.2 to 82.1 vs. 21.9 weeks; 95% CI 0 to 59.8. *p* = 0.095) ([Figure 4](#cancers-12-00344-f004){ref-type="fig"}B).

From all the variables evaluated in our study, the burst of CD4 T~HD~ cells was very significantly associated with patients with G2 profile (46.4% vs. 0%, *p* \< 0.0001) and with patients treated with atezolizumab than with pembrolizumab or nivolumab (41.7% vs. 11.1% vs. 6.7% respectively, *p* = 0.005), and significantly associated with PD-L1 tumor expression \< 5% (34.6% vs. 9.1%, *p* = 0.036). The hazard ratio for progression or death of patients with CD4 T~HD~ burst maintained statistical significance by multivariate analyses (HR 6.749, 95% CI 1.678 to 27.139; *p* = 0.007), when adjusted for gender, smoking habit, tumor histology, immunotherapy drug, line of treatment, number of organs affected, liver metastases, NLR, serum LDH, serum albumin, GRIm Score, G2 lymphocyte profile, and radiological HPD, as did PD-L1 expression ≥ 5%, with HR of 0.287 (95% CI 0.093 to 0.887).

To confirm that the CD4 T~HD~ burst was associated with a greater increase in tumor burden, we compared the TGRs in non-responder patients with and without CD4 T~HD~ burst. As expected, the TGR was significantly higher for patients with observed CD4 T~HD~ burst (1.70 vs. 0.86, *p* = 0.0119) ([Figure 4](#cancers-12-00344-f004){ref-type="fig"}C). This difference was similar and kept statistical significance when only progressors were included (median 1.70 vs. 1.03, *p* = 0.0126) ([Figure 4](#cancers-12-00344-f004){ref-type="fig"}C). Finally, we analyzed the value of CD28-negative CD4 cell quantification as a complementing factor for the diagnosis of HPD in combination with radiological criteria. Patients who presented both HPD by TGR and CD4 T~HD~ burst had significantly lower OS when compared with the rest of patients (24-week OS 15.2% vs. 76.1%, *p* = 0.016) ([Figure 4](#cancers-12-00344-f004){ref-type="fig"}D) and median PFS when considering only progressors (8.1 vs. 6 weeks, *p* = 0.033) ([Figure 4](#cancers-12-00344-f004){ref-type="fig"}E).

These findings support the importance of establishing an immunological profile based on quantification of highly-differentiated CD4 populations. The dynamic changes of highly differentiated CD4 T cell subpopulations induced by immunotherapy are associated with adverse outcomes to PD-1/PD-L1 targeted immunotherapy, with a good correlation with radiological criteria.

3. Discussion {#sec3-cancers-12-00344}
=============

Immunotherapy is fast advancing to front-line therapy in NSCLC. Two studies, including our previous one, showed that a systemic expansion of CD28+ T cell populations occurs in objective responders to PD-L1/PD-1 blockade therapies \[[@B8-cancers-12-00344],[@B14-cancers-12-00344]\]. Therefore, in this exploratory study, we decided to monitor whether an increase in CD28-negative populations was a concomitant marker for failure of PD-L1/PD-1 immunotherapy, and more specifically, to hyperprogressive disease. HPD is one of the most serious adverse events of high clinical importance, but is the subject of intense debate. An incidence of HPD in NSCLC between 10--25% has been previously reported \[[@B4-cancers-12-00344],[@B7-cancers-12-00344],[@B15-cancers-12-00344],[@B16-cancers-12-00344]\], which is in agreement with our observations. Different radiological criteria have identified HPD and its association with markedly worse PFS and OS \[[@B1-cancers-12-00344],[@B2-cancers-12-00344],[@B6-cancers-12-00344],[@B7-cancers-12-00344],[@B15-cancers-12-00344],[@B16-cancers-12-00344]\]. However, the intrinsic characteristics of radiological evaluation, along with the limitations of RECIST criteria, make the diagnosis of HPD challenging, with dramatic consequences. The patient must have at least one measurable lesion in the basal CT scan. To detect the increase in growth of target lesions, a previous radiological control is required, which is not always available. Importantly, tumor growth during this pre-immunotherapy period might have been slowed down by the treatment received, and might be a confounding factor that causes an overestimation of HPD incidence. New lesions that appear after the beginning of immunotherapy are not considered, nor are non-measurable lesions that might significantly increase tumor burden. As a consequence, some HPD patients will not be detected in routine clinical practice. Finally, HPD might be underestimated when tumor burden is high, and the opposite if tumor burden is low, as small absolute changes in diameter would entail much greater relative variations.

Several recent preclinical and clinical studies have put forward immunological mechanisms underlying HPD of varying nature, thereby giving strength to previously published works on this matter \[[@B4-cancers-12-00344],[@B5-cancers-12-00344]\]. The identification of these mechanisms is of the great value. However, these studies rely on biopsies, and it is difficult to translate their data into clinical practice. The identification of systemic immunological biomarkers that would help in identifying HPD would also enable an earlier diagnosis that could complement radiological evaluations.

In agreement with other studies \[[@B14-cancers-12-00344]\], we have recently shown that CD28+ CD4 T cell populations expand in peripheral blood in objective responders to PD-L1/PD-1 blockade therapies \[[@B8-cancers-12-00344]\]. Systemic CD4 T cell profiling allowed us to select groups of patients who were susceptible for PD-L1/PD-1 blockade. Therefore, here, we tested whether the concomitant expansion of CD28-negative CD4 T cells was a biomarker for progression. We found a good association of expansion of this population in peripheral blood with hyperprogressive disease. More specifically, a significant increase in CD28-negative CD4 T cells between baseline and the first cycle of therapy (CD4 T~HD~ burst) was associated with HPD. In this study, we also quantified the relative proportions and changes of other systemic immune populations including neutrophils, monocytes, HLA DR+ cells, and absolute T cell counts. No significant associations were found, as corroborated also by a lack of association with neutrophil-to-lymphocyte ratio, a typical prognostic variable.

Besides its correlation with HPD, we found that all patients with a systemic CD4 T~HD~ burst present disease progression within two months. In fact, the CD4 T~HD~ burst was an independent variable associated with progression by multivariate analysis. Nevertheless, our prospective study is exploratory in nature with a limited number of HPD patients. In addition, the identification of HPD is challenging, and not all studies follow the same criteria. Indeed, many HPD patients progress so rapidly that they cannot be objectively diagnosed before death. Therefore, if validated, the quantification of this systemic immunological phenomenon would lead to the interruption of treatment. To our knowledge, this is the first study associating HPD and the systemic dynamics of CD4 T cell populations. Furthermore, no prospective works regarding this issue have previously been published. Recently, Kim and collaborators linked HPD with the expansion of severely exhausted PD-1+ TIGIT+ CD8+ T cells in Asian populations \[[@B15-cancers-12-00344],[@B16-cancers-12-00344]\]. The different immunological characteristics that have been associated with HPD in several studies indicate that it is a complex phenomenon with different players in the immune system. Indeed, all of these immunological phenomena may be different aspects of an otherwise a common dysfunctional mechanism of immunotherapies leading to HPD, as T cell dysfunction seems to be a shared consequence of all the proposed mechanisms. Although our study does not address whether CD4 T~HD~ cells are directly involved in the onset of HPD, these cells provide a biomarker that changes within the G2 cohort in HPD patients.

4. Materials and Methods {#sec4-cancers-12-00344}
========================

4.1. Study Design {#sec4dot1-cancers-12-00344}
-----------------

The study was approved by the Ethics Committee at the Hospital Complex of Navarre (Pyto2017/49). Informed consent was obtained from all subjects, and all experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. Samples were collected by the Blood and Tissue Bank of Navarre, Health Department of Navarre, Spain. Data and blood samples were prospectively collected from 70 Caucasian patients with locally advanced or metastatic NSCLC treated with ICI (nivolumab, pembrolizumab, atezolizumab) following current indications \[[@B17-cancers-12-00344],[@B18-cancers-12-00344],[@B19-cancers-12-00344]\] at the Complejo Hospitalario de Navarra between September 2017 and May 2019.

Eligible patients were 18 years of age or older, and had all progressed to first-line platinum-based chemotherapy or concurrent chemoradiotherapy. A basal CT scan before the beginning of immunotherapy and a previous one were analyzed. Exclusion criteria were previous immunotherapy treatment or the existence of synchronous neoplasms.

Four milliliters of peripheral blood samples were obtained immediately prior to the infusion of the first cycle of immunotherapy and before the administration of the second. Follow-up concluded with the withdrawal of consent or after death of the patient.

4.2. Sample Processing and Flow Cytometry {#sec4dot2-cancers-12-00344}
-----------------------------------------

Surface and intracellular flow cytometry analyses were performed as described \[[@B20-cancers-12-00344],[@B21-cancers-12-00344]\]. Four milliliters of blood samples were collected from each patient, and PBMCs were isolated by FICOL gradients right after the blood extraction. PBMCs were washed and cells immediately stained with the indicated antibodies in a final volume of 50 μL for 10 min in ice. Cells were washed twice, resuspended in 100 μL of PBS, and analyzed immediately.

The following fluorochrome-conjugated antibodies were used at 1:50 dilutions unless otherwise stated: CD4-APC-Vio770 (clone M-T466, reference 130-100-455, Miltenyi Biotec, Bergisch Gladbach, Germany), CD3-APC (clone REA613, reference 130-113-135, Miltenyi Biotec), CD27-PE (clone M-T271, reference 130-093-185, Miltenyi Biotec), CD28-PECy7 (clone CD28.2, reference 302926, BioLegend, San Diego, CA, USA), CD8-FITC (clone SDK1, reference 344703, BioLegend).

Relative percentage of T cell differentiation subsets based on expression of these markers were quantified using FlowJo \[[@B11-cancers-12-00344],[@B12-cancers-12-00344]\]. The changes in the relative T cell differentiation subsets after the first cycle of immunotherapy were normalized and expressed as a proportion of the percentage of the T cell subset posttreatment divided by the pretreatment percentage (% CD4~HD~ posttreatment / % CD4~HD~ pretreatment), hereafter referred to as ΔCD4 T~HD~.

4.3. Radiological Evaluation {#sec4dot3-cancers-12-00344}
----------------------------

Assessment of response was performed following standard protocols, and according to common clinical practice as decided by the treating oncologist. Tumor responses were evaluated according to RECIST 1.1 \[[@B22-cancers-12-00344]\] and Immune-Related Response Criteria \[[@B23-cancers-12-00344]\]. The TGR was calculated according to the definition by Ferté et al. \[[@B24-cancers-12-00344]\], and measured before and after ICI treatment. HPD was defined as Immune-Related Response Criteria progression at first radiological evaluation with a ≥2-fold increase of the TGR after the beginning of immunotherapy, as proposed by Champiat S et al. \[[@B1-cancers-12-00344]\].

4.4. Statistical Analyses {#sec4dot4-cancers-12-00344}
-------------------------

The association between qualitative variables was evaluated with Pearson's Chi Squared test. The correlation of quantitative variables was studied with a t test for independent samples/ANOVA (if normally distributed) or *U* of Mann--Whitney/Kruskal--Wallis (if not normally distributed, or data with intrinsic high variability). Two-tailed tests were applied. Survival curves were represented by Kaplan-Meier plots, and compared between cohorts with log-rank tests. Hazard ratios were estimated by Cox regression models. Receiver operating characteristics (ROC) analysis was performed with the proportion that represented the changes in T cell subsets after ICI treatment.

5. Conclusions {#sec5-cancers-12-00344}
==============

Our results support HPD as a specific deleterious outcome of PD-1/PD-L1 targeted immunotherapy, and imply the participation of CD4 T cells. We also confirm that the radiological criterion of HPD by TGR calculation accurately predicted fast progression and correlated with lower OS in our cohort. A CD4 T~HD~ burst is associated with HPD, and its combination with radiological criteria might advance procedures used in the detection of HPD and facilitate decision making in controversial situations.

We sincerely thank the patients and families that generously agreed to take part in this study. We are thankful as well to the nursing staff of the Medical Oncology Day Care at Hospital Complex of Navarre for their willful collaboration. We also thank the Blood and Tissue Bank of Navarre, Health Department of Navarre, Spain.

The following are available online at <https://www.mdpi.com/2072-6694/12/2/344/s1>, Figure S1: Kaplan-Meier plot for PFS representing immunotherapy-treated patients classified as indicated and, stratified by the incidence of CD4 THD burst (≥1.3).
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![Hyperprogressive disease as defined by TGR associates with worse PFS and OS. (**A**) Kaplan-Meier plot for PFS in patients with measurable disease by RECIST 1.1 treated with immunotherapy, stratified by HPD at first radiological evaluation. (**B**) Kaplan-Meier plot for PFS only representing those patients with measurable disease by RECIST 1.1 who did not respond to immunotherapy. (**C**) Kaplan-Meier plot for OS in patients with measurable disease by RECIST 1.1 treated with immunotherapy, stratified by HPD at first radiological evaluation.](cancers-12-00344-g001){#cancers-12-00344-f001}

###### 

Hyperprogressive disease as defined by TGR associates with G2 baseline CD4 T~HD~ profiles. (**A**) Dot plot of color-coded clinical outcomes of the patients in our cohort represented by their baseline percentage of CD4 T~HD~ in peripheral blood and TGR. The square with dotted lines represents patients with TGRs higher than 2, the most commonly used cut-off value to separate progressors from hyperprogressors. The horizontal dotted line separates the G1 cohort (\>40% CD4 T~HD~) from the G2 cohort (\<40% CD4 T~HD~). The association of HPD with G2 profiles including also responders is shown below by the Fisher's exact test. OR, objective responses; No OR, no objective responses; HP, hyperprogressors. (**B**) As in (**A**) but plotting the baseline percentage of CD8 T~HD~ cells. No significant association with HPD is observed. (**C**) Contingency table representing the incidence of HPD in patients with measurable disease by RECIST 1.1, according to G1 or G2 lymphocyte profile as defined by Zuazo M. The numbers indicate the following: absolute number of patients, row percentage, and 95% confidence interval of each percentage.
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###### 

An expansion of the CD28^negative^ CD4 T cell compartment following the first cycle of immunotherapy correlates with radiological HPD. (**A**) Example of quantification of CD4 T cells according to CD28 and CD27 expression profiles in a HPD patient before starting immunotherapy (left plot, baseline) and after the first cycle of treatment (right plot); CD4 T~HD~ cells are encircled and correspond to doubly CD28/CD27-negative cells. An increase in CD4 T~HD~ cells was observed (from 5% to 30%, as indicated). (**B**) Same as (**A**) but from a G2 non-HPD progressor. No increase in CD4 T~HD~ cells was observed. (**C**) Bar graph representing the mean and 95% confidence interval of the CD4 T~HD~ proportion in patients who presented HPD compared with non-HPD progressors. (**D**) Bar graph representing mean and 95% confidence interval of the proportion of basal and post-first cycle CD4 T~HD~ cells in patients with partial response, stable disease, progressive disease or HPD. (**E**) ROC analysis of CD4 T~HD~ proportion as a function of radiological HPD. (**F**) Kaplan-Meier plot for PFS in patients with lymphocyte subpopulations quantified before and after the first cycle of immunotherapy, stratified by the detection of CD4 T~HD~ burst (≥1.3). PR: partial response. SD: Stable disease. PD: Progressive disease. HPD: Hyperprogressive disease. \*\*; \*\*\*, indicate very significant (*p* \< 0.01) and highly significant (*p* \< 0.001) statistical differences respectively.
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![The CD4 T~HD~ burst is associated with HPD, and complements radiological criteria for its diagnosis. (**A**) Kaplan-Meier plot for PFS only representing patients with processed lymphocyte subpopulations quantified before and after the first cycle of immunotherapy who did not respond to immunotherapy, stratified by the incidence of CD4 T~HD~ burst (≥1.3). (**B**) Kaplan-Meier plot for OS in patients with lymphocyte subpopulations quantified before and after the first cycle of immunotherapy, stratified by detection of CD4 T~HD~ burst (≥1.3). (**C**) Left graph, box and whiskers plot (Tukey) representing median TGR of patients with CD4 T~HD~ burst compared to the rest of patients. Box depicts interquartile range, whiskers add up 1.5 interquartile range. Outliers are represented by dots. Right graph, same as left but comparing median TGR of patients with CD4 T~HD~ burst compared to the patients that presented progressive disease as best response. (**D**) Kaplan-Meier plot for OS in patients with measurable disease by RECIST 1.1 and lymphocyte subpopulations quantified before and after the first cycle of immunotherapy, stratified by the presence of both HPD by TGR and the detection of CD4 T~HD~ burst (≥1.3). (**E**) Kaplan-Meier plot for PFS representing patients with measurable disease by RECIST 1.1 and lymphocyte subpopulations quantified before and after the first cycle of immunotherapy, who presented progressive disease as best response, stratified by the presence of both HPD by TGR and the detection of CD4 T~HD~ burst (≥1.3). \*, \*\*, indicate significant (*p* \< 0.05) and very significant (*p* \< 0.01) statistical differences.](cancers-12-00344-g004){#cancers-12-00344-f004}
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###### 

Main characteristics of the cohort.

  Variable                                        Number of Patients (%)
  ----------------------------------------------- ------------------------
  Age                                             
      31--40                                      1 (1.4%)
      41--50                                      2 (2.9%)
      51--60                                      15 (21.4%)
      61--70                                      37 (52.9%)
      71--80                                      13 (18.6%)
      \>80                                        2 (2.9%)
  Gender                                          
      Female                                      18 (25.7%)
      Male                                        52 (74.3%)
  ECOG Performance status                         
      0--1                                        56 (80%)
      2--4                                        14 (20%)
  Smoking Habit                                   
      No                                          6 (8.6%)
      Yes                                         64 (91.4%)
  Tumor Histology                                 
      Non-squamous                                51 (72.9%)
      Squamous                                    19 (27.1%)
  Stage                                           
      Locally Advanced                            1 (1.4%)
      Metastatic                                  69 (98.6%)
  Mutational Status                               
      No                                          68 (97.1%)
      EGFR mutated                                1 (1.4%)
      ROS1 translocated                           1 (1.4%)
  Tumor PD-L1 expression                          
      0%                                          23 (32.9%)
      1--4%                                       7 (10%)
      5--49%                                      13 (18.6%)
      ≥50%                                        11 (15.7%)
      Non-evaluable                               16 (22.9%)
  Immunotherapy Drug                              
      Atezolizumab                                28 (40%)
      Nivolumab                                   33 (47.1%)
      Pembrolizumab                               9 (12.9%)
  Treatment Line                                  
      2nd                                         50 (71.4%)
      3rd                                         16 (22.9%)
      4th or further                              4 (5.7%)
  Number of Tumor Sites                           
      ≤2                                          21 (30%)
      ≥3                                          49 (70%)
  Liver Metastases                                
      No                                          51 (72.9%)
      Yes                                         19 (27.1%)
  Neutrophil to Lymphocyte Ratio (NLR)            
      ≤6                                          51 (72.9%)
      \>6                                         19 (27.1%)
  Lactate Dehydrogenase (serum)                   
      ≤ULN                                        14 (20%)
      \>ULN                                       24 (34.3%)
      Non Available                               32 (45.7%)
  Albumin (serum)                                 
      ≥ 3.5 g/dl                                  41 (58.6%)
      \< 3.5 g/dl                                 12 (17.1%)
      Non Available                               17 (24.3%)
  GRIm Score                                      
      0--1                                        37 (52.9%)
      2--3                                        15 (21.4%)
      Non Evaluable                               18 (25.7%)
  Derived Neutrophil to Lymphocyte Ratio (dNLR)   
      \<3                                         54 (77.1%)
      \>3                                         16 (22.9%)
  Lung Immune Prognostic Index (LIPI)             
      Intermediate/Good Prognosis                 57 (81.4%)
      Poor prognosis                              5 (7.1%)
      Non evaluable                               8 (11.4%)
  Lymphocytes                                     
      Non-lymphopenia                             48 (68.6%)
      Lymphopenia                                 22 (31.4%)
  Lymphocyte Profile                              
      G1                                          37 (52.9%)
      G2                                          31 (44.3%)
      Non-evaluable                               2 (2.9%)

[^1]: These authors contributed equally.
